MARKET

MESO

MESO

Mesoblast
NASDAQ
15.95
-0.13
-0.81%
After Hours: 16.39 +0.44 +2.76% 17:36 02/06 EST
OPEN
15.74
PREV CLOSE
16.08
HIGH
16.07
LOW
15.55
VOLUME
283.98K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
9.61
MARKET CAP
2.06B
P/E (TTM)
-18.8601
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MESO last week (0126-0130)?
Weekly Report · 6d ago
*Mesoblast Price Target Raised 11% to A$4.45/Share by Bell Potter
Dow Jones · 01/29 22:55
Mesoblast Lifts Ryoncil Revenues, Secures Cheaper Credit and Advances Late-Stage Cell Therapy Pipeline
TipRanks · 01/29 13:44
Mesoblast Reports US$30 Million Net Revenue for Second Fiscal Quarter 2026
Reuters · 01/28 23:54
Mesoblast Reports 84% Survival in Early Real‑World Use of Ryoncil for Pediatric SR‑aGvHD
TipRanks · 01/28 20:47
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Barchart · 01/28 17:54
Largest borrow rate increases among liquid names
TipRanks · 01/28 13:45
Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication
Benzinga · 01/27 18:01
More
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.